Follow
Pascal Furet
Pascal Furet
Director and leading scientist at Novartis
Verified email at novartis.com
Title
Cited by
Cited by
Year
Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo …
SM Maira, F Stauffer, J Brueggen, P Furet, C Schnell, C Fritsch, ...
Molecular cancer therapeutics 7 (7), 1851-1863, 2008
13442008
In vivo antitumor activity of NVP-AEW541—a novel, potent, and selective inhibitor of the IGF-IR kinase
C Garcı́a-Echeverrı́a, MA Pearson, A Marti, T Meyer, J Mestan, ...
Cancer cell 5 (3), 231-239, 2004
6542004
Strategies toward the design of novel and selective protein tyrosine kinase inhibitors
P Traxler, P Furet
Pharmacology & therapeutics 82 (2-3), 195-206, 1999
5051999
The allosteric inhibitor ABL001 enables dual targeting of BCR–ABL1
AA Wylie, J Schoepfer, W Jahnke, SW Cowan-Jacob, A Loo, P Furet, ...
Nature 543 (7647), 733-737, 2017
4862017
Discovery of 3-(2, 6-dichloro-3, 5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor …
V Guagnano, P Furet, C Spanka, V Bordas, M Le Douget, C Stamm, ...
Journal of medicinal chemistry 54 (20), 7066-7083, 2011
4862011
Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials
C Fritsch, A Huang, C Chatenay-Rivauday, C Schnell, A Reddy, M Liu, ...
Molecular cancer therapeutics 13 (5), 1117-1129, 2014
4672014
Protein kinases as targets for anticancer agents: from inhibitors to useful drugs
D Fabbro, S Ruetz, E Buchdunger, SW Cowan-Jacob, G Fendrich, ...
Pharmacology & therapeutics 93 (2-3), 79-98, 2002
4622002
Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion–Positive Cholangiocarcinoma
L Goyal, SK Saha, LY Liu, G Siravegna, I Leshchiner, LG Ahronian, ...
Cancer discovery 7 (3), 252-263, 2017
458*2017
Tyrosine kinase inhibitors: from rational design to clinical trials
P Traxler, G Bold, E Buchdunger, G Caravatti, P Furet, P Manley, ...
Medicinal research reviews 21 (6), 499-512, 2001
4212001
Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation
P Furet, V Guagnano, RA Fairhurst, P Imbach-Weese, I Bruce, M Knapp, ...
Bioorganic & medicinal chemistry letters 23 (13), 3741-3748, 2013
4112013
Different susceptibility of protein kinases to staurosporine inhibition: kinetic studies and molecular bases for the resistance of protein kinase CK2
F Meggio, AD Deana, M Ruzzene, AM Brunati, L Cesaro, B Guerra, ...
European Journal of Biochemistry 234 (1), 317-322, 1995
3541995
Discovery of asciminib (ABL001), an allosteric inhibitor of the tyrosine kinase activity of BCR-ABL1
J Schoepfer, W Jahnke, G Berellini, S Buonamici, S Cotesta, ...
Journal of Medicinal Chemistry 61 (18), 8120-8135, 2018
3322018
Imatinib: a selective tyrosine kinase inhibitor
PW Manley, SW Cowan-Jacob, E Buchdunger, D Fabbro, G Fendrich, ...
European journal of cancer 38, S19-S27, 2002
3292002
New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis
G Bold, KH Altmann, J Frei, M Lang, PW Manley, P Traxler, B Wietfeld, ...
Journal of medicinal chemistry 43 (12), 2310-2323, 2000
3252000
Discovery of potent antagonists of the interaction between human double minute 2 and tumor suppressor p53
C Garcia-Echeverria, P Chene, MJJ Blommers, P Furet
Journal of medicinal chemistry 43 (17), 3205-3208, 2000
3242000
Use of a pharmacophore model for the design of EGF-R tyrosine kinase inhibitors: 4-(phenylamino) pyrazolo [3, 4-d] pyrimidines
P Traxler, G Bold, J Frei, M Lang, N Lydon, H Mett, E Buchdunger, ...
Journal of medicinal chemistry 40 (22), 3601-3616, 1997
3161997
Structural biology contributions to the discovery of drugs to treat chronic myelogenous leukaemia
SW Cowan-Jacob, G Fendrich, A Floersheimer, P Furet, J Liebetanz, ...
Acta Crystallographica Section D: Biological Crystallography 63 (1), 80-93, 2007
3092007
Discovery of a potent and selective protein kinase CK2 inhibitor by high-throughput docking
E Vangrevelinghe, K Zimmermann, J Schoepfer, R Portmann, D Fabbro, ...
Journal of medicinal chemistry 46 (13), 2656-2662, 2003
2892003
Structural basis for specificity of Grb2-SH2 revealed by a novel ligand binding mode
J Rahuel, B Gay, D Erdmann, A Strauss, C García-Echeverría, P Furet, ...
Nature structural biology 3 (7), 586-589, 1996
2861996
Extended kinase profile and properties of the protein kinase inhibitor nilotinib
PW Manley, P Drueckes, G Fendrich, P Furet, J Liebetanz, ...
Biochimica et Biophysica Acta (BBA)-Proteins and Proteomics 1804 (3), 445-453, 2010
2602010
The system can't perform the operation now. Try again later.
Articles 1–20